Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGFR VEDVsPNU+EDVs40 mer

Next Previous
Drug Profile

EGFR VEDVsPNU+EDVs40 mer

Alternative Names: D682-carrying EDV™ - EnGeneIC; Designer EDVTM; E-EDV-D682; E-EDV-D682 - EnGeneIC; EGFR VEDVsPNU; EGFR-VEDVsPNU-EnGeneIC; PNU-159682

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EnGeneIC
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adenocarcinoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 12 Jan 2026 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT07049055)
  • 30 Jun 2025 Engeneic Pty plans a phase I/IIa Carolyn-USA trial for Pancreatic cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA(IV) in September 2025 (NCT07049055)
  • 13 May 2025 Phase-I/II clinical trials in Solid tumours (Adjuvant therapy, Late-stage disease, Second-line therapy or greater) in Australia (IV) (ACTRN12625000203459)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top